{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:23:23Z","timestamp":1791685403309,"version":"4.3.4"},"reference-count":273,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13346-024-01780-x","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T13:39:40Z","timestamp":1737639580000},"page":"1935-1961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Navigating liver cancer: Precision targeting for enhanced treatment outcomes"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8131-1860","authenticated-orcid":false,"given":"Ankit","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Hurkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Shilpi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi","family":"Mody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"1780_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.livres.2023.07.004","volume":"7","author":"F Chen","year":"2023","unstructured":"Chen F, Li Q, Xu X, Wang F. Clinical characteristics and risk factors of hepatitis B virus-related cirrhosis\/hepatocellular carcinoma: A single-center retrospective study. Liver Research. 2023;7:237\u201343.","journal-title":"Liver Research"},{"key":"1780_CR2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/j.jhep.2022.12.002","volume":"78","author":"C Li","year":"2023","unstructured":"Li C, He W-Q. Global prediction of primary liver cancer incidences and mortality in 2040. J Hepatol. 2023;78:e144\u20136.","journal-title":"J Hepatol"},{"key":"1780_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"1780_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","volume":"13","author":"F Bray","year":"2012","unstructured":"Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study. Lancet Oncol. 2012;13:790\u2013801.","journal-title":"Lancet Oncol"},{"key":"1780_CR5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejpb.2008.05.004","volume":"70","author":"L Yuan","year":"2008","unstructured":"Yuan L, Wang J, Shen W-C. Reversible lipidization of somatostatin analogues for the liver targeting. Eur J Pharm Biopharm. 2008;70:615\u201320.","journal-title":"Eur J Pharm Biopharm"},{"key":"1780_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2147\/IJN.S236927","volume":"15","author":"U Ruman","year":"2020","unstructured":"Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities. Inte J Nanomed. 2020;15:1437\u201356.","journal-title":"Inte J Nanomed"},{"key":"1780_CR7","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1038\/s41467-023-41771-z","volume":"14","author":"SK Thomas","year":"2023","unstructured":"Thomas SK, Wattenberg MM, Choi-Bose S, Uhlik M, Harrison B, Coho H, et al. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nat Commun. 2023;14:6330.","journal-title":"Nat Commun"},{"key":"1780_CR8","doi-asserted-by":"publisher","first-page":"111342","DOI":"10.1016\/j.biopha.2021.111342","volume":"137","author":"W Peng","year":"2021","unstructured":"Peng W, Cheng S, Bao Z, Wang Y, Zhou W, Wang J, et al. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomed Pharmacother. 2021;137:111342.","journal-title":"Biomed Pharmacother"},{"key":"1780_CR9","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","volume":"134","author":"HB El-Serag","year":"2008","unstructured":"El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752\u201363.","journal-title":"Gastroenterology"},{"key":"1780_CR10","doi-asserted-by":"publisher","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophy Acta (BBA) - Rev Cancer. 2020;1873:188314.","journal-title":"Biochim Biophy Acta (BBA) - Rev Cancer."},{"key":"1780_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2741\/e798","volume":"9","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Singh SK, Chowdhury I, Lillard JW Jr, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed). 2017;9:235.","journal-title":"Front Biosci (Elite Ed)"},{"key":"1780_CR12","doi-asserted-by":"publisher","first-page":"105766","DOI":"10.1016\/j.jddst.2024.105766","volume":"97","author":"R Singh","year":"2024","unstructured":"Singh R, Mishra AK, Bhushan B, Rawat H, Kumar V. A glance on gold nanoparticle: An emerging theranostic tool for oncology. J Drug Deliv Sci Technol. 2024;97:105766.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1780_CR13","doi-asserted-by":"publisher","first-page":"100777","DOI":"10.1016\/j.drup.2021.100777","volume":"58","author":"Z Su","year":"2021","unstructured":"Su Z, Dong S, Zhao S-C, Liu K, Tan Y, Jiang X, et al. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updates. 2021;58:100777.","journal-title":"Drug Resist Updates"},{"key":"1780_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2012.05.007","volume":"39","author":"BI Carr","year":"2012","unstructured":"Carr BI. Some new approaches to the management of hepatocellular carcinoma. Semin Oncol. 2012;39:369\u201373. https:\/\/doi.org\/10.1053\/j.seminoncol.2012.05.007.","journal-title":"Semin Oncol."},{"key":"1780_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.chemphyslip.2016.10.005","volume":"201","author":"A Jain","year":"2016","unstructured":"Jain A, Jain SK. In vitro release kinetics model fitting of liposomes: an insight. Chem Phys Lipid. 2016;201:28\u201340.","journal-title":"Chem Phys Lipid"},{"key":"1780_CR16","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.xphs.2020.10.002","volume":"110","author":"AM Fatouh","year":"2021","unstructured":"Fatouh AM, Elshafeey AH, Abdelbary A. Galactosylated chitosan coated liposomes of ledipasvir for liver targeting: chemical synthesis, statistical optimization, in-vitro and in-vivo evaluation. J Pharm Sci. 2021;110:1148\u201359.","journal-title":"J Pharm Sci"},{"key":"1780_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.7150\/thno.37301","volume":"10","author":"M Wang","year":"2020","unstructured":"Wang M, Zhang M, Fu L, Lin J, Zhou X, Zhou P, et al. Liver-targeted delivery of TSG-6 by calcium phosphate nanoparticles for the management of liver fibrosis. Theranostics. 2020;10:36.","journal-title":"Theranostics"},{"key":"1780_CR18","doi-asserted-by":"publisher","first-page":"104580","DOI":"10.1016\/j.jddst.2023.104580","volume":"86","author":"AK Mishra","year":"2023","unstructured":"Mishra AK, Neha SL, Rani L, Jain A, Dewangan HK, Sahoo PK. Rationally designed nanoparticulate delivery approach for silymarin with natural bio-enhancer: In vitro characterization and in vivo evaluations of hepatoprotective effects in a mouse model. J Drug Deliv Sci Technol. 2023;86:104580.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1780_CR19","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1021\/acs.biomac.1c00649","volume":"22","author":"R Sharma","year":"2021","unstructured":"Sharma R, Porterfield JE, An H-T, Jimenez AS, Lee S, Kannan S, et al. Rationally designed galactose dendrimer for hepatocyte-specific targeting and intracellular drug delivery for the treatment of liver disorders. Biomacromol. 2021;22:3574\u201389.","journal-title":"Biomacromol"},{"key":"1780_CR20","doi-asserted-by":"publisher","first-page":"102493","DOI":"10.1016\/j.jddst.2021.102493","volume":"63","author":"G Ma","year":"2021","unstructured":"Ma G, Du X, Zhu J, Xu F, Yu H, Li J. Multi-functionalized dendrimers for targeted co-delivery of sorafenib and paclitaxel in liver cancers. J Drug Deliv Sci Technol. 2021;63:102493.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1780_CR21","doi-asserted-by":"publisher","first-page":"134826","DOI":"10.1016\/j.chemosphere.2022.134826","volume":"302","author":"E Ahmadian","year":"2022","unstructured":"Ahmadian E, Janas D, Eftekhari A, Zare N. Application of carbon nanotubes in sensing\/monitoring of pancreas and liver cancer. Chemosphere. 2022;302:134826.","journal-title":"Chemosphere"},{"key":"1780_CR22","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.arabjc.2021.103649","volume":"15","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Vinothini K, Dou F, Jing Y, Chuturgoon AA, Arumugam T, et al. Hyper-branched multifunctional carbon nanotubes carrier for targeted liver cancer therapy. Arab J Chem. 2022;15:103649.","journal-title":"Arab J Chem"},{"key":"1780_CR23","doi-asserted-by":"publisher","first-page":"120761","DOI":"10.1016\/j.biomaterials.2021.120761","volume":"271","author":"L Sun","year":"2021","unstructured":"Sun L, Fan M, Huang D, Li B, Xu R, Gao F, et al. Clodronate-loaded liposomal and fibroblast-derived exosomal hybrid system for enhanced drug delivery to pulmonary fibrosis. Biomaterials. 2021;271:120761.","journal-title":"Biomaterials"},{"key":"1780_CR24","doi-asserted-by":"publisher","first-page":"E4601","DOI":"10.1073\/pnas.1603316113","volume":"113","author":"Q Yin","year":"2016","unstructured":"Yin Q, Tang L, Cai K, Tong R, Sternberg R, Yang X, et al. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc Natl Acad Sci U S A. 2016;113:E4601\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1780_CR25","doi-asserted-by":"publisher","first-page":"11628","DOI":"10.1021\/acsnano.5b04866","volume":"9","author":"J Key","year":"2015","unstructured":"Key J, Palange AL, Gentile F, Aryal S, Stigliano C, Di Mascolo D, et al. Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors. ACS Nano. 2015;9:11628\u201341.","journal-title":"ACS Nano"},{"key":"1780_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007706","volume":"30","author":"VK Sharma","year":"2013","unstructured":"Sharma VK, Jain A, Soni V. Nano-aggregates: emerging delivery tools for tumor therapy. Crit Rev Ther Drug Carrier Syst. 2013;30:535\u201363.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1780_CR27","doi-asserted-by":"publisher","first-page":"119781","DOI":"10.1016\/j.ijpharm.2020.119781","volume":"588","author":"KR Gajbhiye","year":"2020","unstructured":"Gajbhiye KR, Chaudhari BP, Pokharkar VB, Pawar A, Gajbhiye V. Stimuli-responsive biodegradable polyurethane nano-constructs as a potential triggered drug delivery vehicle for cancer therapy. Int J Pharm. 2020;588:119781.","journal-title":"Int J Pharm"},{"key":"1780_CR28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1053\/j.seminoncol.2015.09.027","volume":"42","author":"C Hierro","year":"2015","unstructured":"Hierro C, Rodon J, Tabernero J. Fibroblast Growth Factor (FGF) Receptor\/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol. 2015;42:801\u201319. https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.027.","journal-title":"Semin Oncol."},{"key":"1780_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4254\/wjh.v3.i2.38","volume":"3","author":"A Pircher","year":"2011","unstructured":"Pircher A, Medinger M, Drevs J. Liver cancer: Targeted future options. World J Hepatol. 2011;3:38\u201344.","journal-title":"World J Hepatol"},{"key":"1780_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.intimp.2014.12.024","volume":"24","author":"R Chatterjee","year":"2015","unstructured":"Chatterjee R, Mitra A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int Immunopharmacol. 2015;24:335\u201345.","journal-title":"Int Immunopharmacol"},{"key":"1780_CR31","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.1007\/s11033-023-08666-0","volume":"50","author":"SS Tamber","year":"2023","unstructured":"Tamber SS, Bansal P, Sharma S, Singh RB, Sharma R. Biomarkers of liver diseases. Mol Biol Rep. 2023;50:7815\u201323.","journal-title":"Mol Biol Rep"},{"key":"1780_CR32","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","volume":"55","author":"A Alqahtani","year":"2019","unstructured":"Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular carcinoma: molecular mechanisms and targeted therapies. Medicina. 2019;55:526.","journal-title":"Medicina."},{"key":"1780_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","volume":"12","author":"JM Llovet","year":"2015","unstructured":"Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1780_CR34","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2174\/1389450119666180131105822","volume":"19","author":"A Jain","year":"2018","unstructured":"Jain A, Kumari R, Tiwari A, Verma A, Tripathi A, Shrivastava A, Jain SK. Nanocarrier based advances in drug delivery to tumor: an overview. Current drug targets. 2018;19:1498\u2013518. https:\/\/doi.org\/10.2174\/1389450119666180131105822.","journal-title":"Current drug targets."},{"key":"1780_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2174\/1566524015666150831131320","volume":"15","author":"A Jain","year":"2015","unstructured":"Jain A, Jain SK. Colon targeted liposomal systems (CTLS): Theranostic potential. Curr Mol Med. 2015;15:621\u201333.","journal-title":"Curr Mol Med"},{"key":"1780_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0378-5173(03)00085-1","volume":"255","author":"T Ishida","year":"2003","unstructured":"Ishida T, Masuda K, Ichikawa T, Ichihara M, Irimura K, Kiwada H. Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm. 2003;255:167\u201374.","journal-title":"Int J Pharm"},{"key":"1780_CR37","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1007\/s00289-019-02924-7","volume":"77","author":"TU Wani","year":"2020","unstructured":"Wani TU, Raza SN, Khan NA. Nanoparticle opsonization: Forces involved and protection by long chain polymers. Polym Bull. 2020;77:3865\u201389.","journal-title":"Polym Bull"},{"key":"1780_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ijpharm.2007.08.001","volume":"349","author":"FQ Li","year":"2008","unstructured":"Li FQ, Su H, Wang J, Liu JY, Zhu QG, Fei YB, et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int J Pharm. 2008;349:274\u201382.","journal-title":"Int J Pharm"},{"key":"1780_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-015-0221-0","volume":"38","author":"S Derks","year":"2015","unstructured":"Derks S, Diosdado B. Personalized cancer medicine: next steps in the genomic era. Cell Oncol. 2015;38:1\u20132.","journal-title":"Cell Oncol"},{"key":"1780_CR40","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.2174\/1871520617666170713151149","volume":"17","author":"F Zhou","year":"2018","unstructured":"Zhou F, Teng F, Deng P, Meng N, Song Z, Feng R. Recent progress of nano-drug delivery system for liver cancer treatment. Anticancer Agents Med Chem. 2018;17:1884\u201397.","journal-title":"Anticancer Agents Med Chem"},{"key":"1780_CR41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1389450117666160208144143","volume":"19","author":"A Jain","year":"2018","unstructured":"Jain A, Jain SK. Stimuli-responsive Smart Liposomes in Cancer Targeting. Curr Drug Targets. 2018;19:259\u201370.","journal-title":"Curr Drug Targets"},{"key":"1780_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2015010903","volume":"32","author":"A Jain","year":"2015","unstructured":"Jain A, Jain SK. Ligand-Appended BBB-Targeted Nanocarriers (LABTNs). Crit Rev Ther Drug Carrier Syst. 2015;32:149\u201380.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1780_CR43","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.2174\/1389450119666180131105822","volume":"19","author":"A Jain","year":"2018","unstructured":"Jain A, Kumari R, Tiwari A, Verma A, Tripathi A, Shrivastava A, et al. Nanocarrier based advances in drug delivery to tumor: an overview. Curr Drug Targets. 2018;19:1498\u2013518.","journal-title":"Curr Drug Targets"},{"key":"1780_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2014.122-c2","volume":"12","author":"A Forner","year":"2015","unstructured":"Forner A, Gilabert M, Bruix J, Raoul JL. Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. Nat Rev Clin Oncol. 2015;12:10.","journal-title":"Nat Rev Clin Oncol"},{"key":"1780_CR45","doi-asserted-by":"publisher","unstructured":"Dogeas E, Choti MA. Management of Primary Malignant Hepatic Neoplasms Other Than Hepatocellular Cancer. InShackelford's Surgery of the Alimentary Tract, 2 Volume Set 2019;1:1556-1564. https:\/\/doi.org\/10.1016\/B978-0-323-40232-3.00133-3.","DOI":"10.1016\/B978-0-323-40232-3.00133-3"},{"key":"1780_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/ncponc0844","volume":"4","author":"M Schwartz","year":"2007","unstructured":"Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424\u201332.","journal-title":"Nat Clin Pract Oncol"},{"key":"1780_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2036.2009.04200.x","volume":"31","author":"R Cabrera","year":"2010","unstructured":"Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;31:461\u201376.","journal-title":"Aliment Pharmacol Ther"},{"key":"1780_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380.","journal-title":"Hepatology"},{"key":"1780_CR49","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208\u201336.","journal-title":"Hepatology"},{"key":"1780_CR50","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ctrv.2006.08.002","volume":"32","author":"L Marelli","year":"2006","unstructured":"Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev. 2006;32:594\u2013606.","journal-title":"Cancer Treat Rev"},{"key":"1780_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00535-005-1566-3","volume":"40","author":"JM Llovet","year":"2005","unstructured":"Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225\u201335.","journal-title":"J Gastroenterol"},{"key":"1780_CR52","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1046\/j.1365-2036.2003.01580.x","volume":"17","author":"P Mathurin","year":"2003","unstructured":"Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot FR, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17:1247\u201361.","journal-title":"Aliment Pharmacol Ther"},{"key":"1780_CR53","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1634\/theoncologist.11-7-790","volume":"11","author":"AX Zhu","year":"2006","unstructured":"Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11:790\u2013800.","journal-title":"Oncologist"},{"key":"1780_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jhep.2012.09.006","volume":"58","author":"A Zaanan","year":"2013","unstructured":"Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58:81\u20138.","journal-title":"J Hepatol"},{"key":"1780_CR55","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293\u2013300.","journal-title":"J Clin Oncol"},{"key":"1780_CR56","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4251\/wjgo.v15.i1.19","volume":"15","author":"HC Lai","year":"2023","unstructured":"Lai HC, Lin HJ, Jeng LB, Huang ST. Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma. World J Gastrointest Oncol. 2023;15:19\u201335.","journal-title":"World J Gastrointest Oncol"},{"key":"1780_CR57","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3389\/fimmu.2019.02525","volume":"10","author":"M Zheng","year":"2019","unstructured":"Zheng M, Tian Z. Liver-mediated adaptive immune tolerance. Front Immunol. 2019;10:2525.","journal-title":"Front Immunol"},{"key":"1780_CR58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jhep.2019.09.025","volume":"72","author":"A-L Cheng","year":"2020","unstructured":"Cheng A-L, Hsu C, Chan SL, Choo S-P, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307\u201319.","journal-title":"J Hepatol"},{"key":"1780_CR59","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3390\/cancers12103025","volume":"12","author":"P Federico","year":"2020","unstructured":"Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, et al. Immune checkpoint inhibitors in hepatocellular carcinoma: current status and novel perspectives. Cancers. 2020;12:3025.","journal-title":"Cancers"},{"key":"1780_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112034","author":"Y Zarlashat","year":"2024","unstructured":"Zarlashat Y, Abbas S, Ghaffar A. Hepatocellular carcinoma: Beyond the border of advanced stage therapy. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16112034.","journal-title":"Cancers"},{"key":"1780_CR61","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/hep.22506","volume":"48","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312\u201327.","journal-title":"Hepatology"},{"key":"1780_CR62","first-page":"170","volume":"23","author":"K Blagotinsek","year":"2017","unstructured":"Blagotinsek K, Rozman D. Targeting signalling pathways in hepatocellular carcinoma. Curr Pharm Des. 2017;23:170\u20135.","journal-title":"Curr Pharm Des"},{"issue":"Suppl 3","key":"1780_CR63","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1016\/S1590-8658(10)60515-4","volume":"42","author":"A Lachenmayer","year":"2010","unstructured":"Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl 3):S264\u201372.","journal-title":"Dig Liver Dis"},{"key":"1780_CR64","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cncr.28480","volume":"120","author":"SS Agarwala","year":"2014","unstructured":"Agarwala SS, Eggermont AM, O\u2019Day S, Zager JS. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer. 2014;120:781\u20139.","journal-title":"Cancer"},{"key":"1780_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12307-008-0011-6","volume":"1","author":"F Vidal-Vanaclocha","year":"2008","unstructured":"Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron. 2008;1:113\u201329.","journal-title":"Cancer Microenviron"},{"key":"1780_CR66","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/hep.22580","volume":"48","author":"RN Aravalli","year":"2008","unstructured":"Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047\u201363.","journal-title":"Hepatology"},{"key":"1780_CR67","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00204-012-0931-2","volume":"87","author":"RN Aravalli","year":"2013","unstructured":"Aravalli RN, Cressman EN, Steer CJ. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2013;87:227\u201347.","journal-title":"Arch Toxicol"},{"key":"1780_CR68","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3748\/wjg.v25.i19.2279","volume":"25","author":"OO Ogunwobi","year":"2019","unstructured":"Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, et al. Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 2019;25:2279\u201393.","journal-title":"World J Gastroenterol"},{"key":"1780_CR69","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/cancers14030621","volume":"14","author":"B Cucarull","year":"2022","unstructured":"Cucarull B, Tutusaus A, Rider P, Hern\u00e1ez-Alsina T, Cu\u00f1o C, Garcia de Frutos P, et al. Hepatocellular carcinoma: molecular pathogenesis and therapeutic advances. Cancers. 2022;14:621.","journal-title":"Cancers."},{"key":"1780_CR70","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0014-5793(99)00364-6","volume":"448","author":"EL Romero","year":"1999","unstructured":"Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 1999;448:193\u20136.","journal-title":"FEBS Lett"},{"key":"1780_CR71","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Can Res. 1986;46:6387\u201392.","journal-title":"Can Res"},{"key":"1780_CR72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controll Release\u202f: Off J Controll Release Soc. 2000;65:271\u201384.","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"1780_CR73","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.drudis.2006.07.005","volume":"11","author":"AK Iyer","year":"2006","unstructured":"Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today. 2006;11:812\u20138.","journal-title":"Drug Discovery Today"},{"key":"1780_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","volume":"130","author":"SK Golombek","year":"2018","unstructured":"Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17\u201338.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR75","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2217\/nnm.15.86","volume":"10","author":"E Huynh","year":"2015","unstructured":"Huynh E, Zheng G. Cancer nanomedicine: addressing the dark side of the enhanced permeability and retention effect. Nanomedicine. 2015;10:1993\u20135. https:\/\/doi.org\/10.2217\/nnm.15.86.","journal-title":"Nanomedicine."},{"key":"1780_CR76","doi-asserted-by":"publisher","unstructured":"Matsumura Y. Principle of CAST strategy. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. 2019; pp 255\u201367. https:\/\/doi.org\/10.1007\/978-4-431-56880-3_11","DOI":"10.1007\/978-4-431-56880-3_11"},{"key":"1780_CR77","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.7150\/thno.52614","volume":"11","author":"A Shah","year":"2021","unstructured":"Shah A, Rauth S, Aithal A, Kaur S, Ganguly K, Orzechowski C, et al. The current landscape of antibody-based therapies in solid malignancies. Theranostics. 2021;11:1493.","journal-title":"Theranostics"},{"key":"1780_CR78","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154\u2013155","author":"R B\u00f6ttger","year":"2020","unstructured":"B\u00f6ttger R, Pauli G, Chao P-H, Al Fayez N, Hohenwarter L, Li S-D. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2019.08.016","volume":"69","author":"MH Elnaggar","year":"2021","unstructured":"Elnaggar MH, Abushouk AI, Hassan AHE, Lamloum HM, Benmelouka A, Moatamed SA, et al. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol. 2021;69:91\u20139.","journal-title":"Semin Cancer Biol"},{"key":"1780_CR80","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.2741\/beljaars","volume":"7","author":"L Beljaars","year":"2002","unstructured":"Beljaars L, Meijer DK, Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci. 2002;7:e214\u201322.","journal-title":"Front Biosci"},{"key":"1780_CR81","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/1389450123666220906091432","volume":"23","author":"AK Mishra","year":"2022","unstructured":"Mishra AK, Pandey M, Dewangan HK, Sl N, Sahoo PK. A Comprehensive review on liver targeting: emphasis on nanotechnology- based molecular targets and receptors mediated approaches. Curr Drug Targets. 2022;23:1381\u2013405.","journal-title":"Curr Drug Targets"},{"key":"1780_CR82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acs.molpharmaceut.0c00980","volume":"18","author":"RA Petrov","year":"2021","unstructured":"Petrov RA, Mefedova SR, Yamansarov EY, Maklakova SY, Grishin DA, Lopatukhina EV, et al. New small-molecule glycoconjugates of docetaxel and GalNAc for targeted delivery to hepatocellular carcinoma. Mol Pharm. 2021;18:461\u20138.","journal-title":"Mol Pharm"},{"key":"1780_CR83","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","volume":"14","author":"CE Samuel","year":"2001","unstructured":"Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778\u2013809 (table of contents).","journal-title":"Clin Microbiol Rev"},{"key":"1780_CR84","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMct061675","volume":"355","author":"JH Hoofnagle","year":"2006","unstructured":"Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444\u201351.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"1780_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000049157","volume":"47","author":"C Scarpignato","year":"2001","unstructured":"Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy. 2001;47(Suppl 2):1\u201329.","journal-title":"Chemotherapy"},{"key":"1780_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/jpm11060571","volume":"11","author":"MA Subhan","year":"2021","unstructured":"Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via EPR effect for cancer treatment. J Person Med. 2021;11:571.","journal-title":"J Person Med"},{"key":"1780_CR87","unstructured":"Jain A, Jain S. Ligand-mediated drug-targeted liposomes. Liposomal Delivery Systems: Advances and Challenges. UK: Future Medicine. 2016; pp 144\u201358."},{"key":"1780_CR88","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/dna.2005.24.271","volume":"24","author":"M Richter","year":"2005","unstructured":"Richter M, Zhang H. Receptor-targeted cancer therapy. DNA Cell Biol. 2005;24:271\u201382.","journal-title":"DNA Cell Biol"},{"key":"1780_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-016-0452-7","volume":"12","author":"SG Swamy","year":"2017","unstructured":"Swamy SG, Kameshwar VH, Shubha PB, Looi CY, Shanmugam MK, Arfuso F, et al. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Target Oncol. 2017;12:1\u201310.","journal-title":"Target Oncol"},{"key":"1780_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/B978-0-12-813753-6.00002-0","volume":"1","author":"N Van Der Steen","year":"2019","unstructured":"Van Der Steen N, Garajova I, Rolfo C, Cavazzoni A, Giovannetti E. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies. InTargeting Cell Survival Pathways to Enhance Response to Chemotherapy. 2019;1:25\u201360. https:\/\/doi.org\/10.1016\/B978-0-12-813753-6.00002-0.","journal-title":"InTargeting Cell Survival Pathways to Enhance Response to Chemotherapy"},{"key":"1780_CR91","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/08941939.2010.542272","volume":"24","author":"ZY Yi","year":"2011","unstructured":"Yi ZY, Feng LJ, Xiang Z, Yao H. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in hepatocellular carcinoma cells. J Investig Surg\u202f: Off J Acad Surg Res. 2011;24:67\u201376.","journal-title":"J Investig Surg : Off J Acad Surg Res"},{"key":"1780_CR92","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1038\/onc.2013.274","volume":"33","author":"C Chang","year":"2014","unstructured":"Chang C, Lee SO, Yeh S, Chang TM. Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene. 2014;33:3225\u201334.","journal-title":"Oncogene"},{"key":"1780_CR93","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00534-009-0236-x","volume":"17","author":"E Liapi","year":"2010","unstructured":"Liapi E, Geschwind JF. Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer. J Hepatobiliary Pancreat Sci. 2010;17:405\u20136.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1780_CR94","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/cgt.2009.68","volume":"17","author":"R Zhang","year":"2010","unstructured":"Zhang R, Ma L, Zheng M, Ren J, Wang T, Meng Y, et al. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther. 2010;17:275\u201388.","journal-title":"Cancer Gene Ther"},{"key":"1780_CR95","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hep.24000","volume":"53","author":"TKW Lee","year":"2011","unstructured":"Lee TKW, Castilho A, Cheung VCH, Tang KH, Ma S, Ng IOL. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology. 2011;53:160\u201370.","journal-title":"Hepatology"},{"key":"1780_CR96","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1021\/mp500394v","volume":"12","author":"W-W Qi","year":"2015","unstructured":"Qi W-W, Yu H-Y, Guo H, Lou J, Wang Z-M, Liu P, et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharm. 2015;12:675\u201383.","journal-title":"Mol Pharm"},{"key":"1780_CR97","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/hep.23419","volume":"51","author":"M Moreno","year":"2010","unstructured":"Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, et al. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology. 2010;51:942\u201352.","journal-title":"Hepatology"},{"key":"1780_CR98","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1021\/bc800237t","volume":"20","author":"N Yang","year":"2009","unstructured":"Yang N, Ye Z, Li F, Mahato RI. HPMA polymer-based site-specific delivery of oligonucleotides to hepatic stellate cells. Bioconjug Chem. 2009;20:213\u201321.","journal-title":"Bioconjug Chem"},{"key":"1780_CR99","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s11095-006-9175-2","volume":"24","author":"WI Hagens","year":"2007","unstructured":"Hagens WI, Mattos A, Greupink R, de Jager-Krikken A, Reker-Smit C, van Loenen-Weemaes A, et al. Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res. 2007;24:566\u201374.","journal-title":"Pharm Res"},{"key":"1780_CR100","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nbt1396","volume":"26","author":"Y Sato","year":"2008","unstructured":"Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008;26:431\u201342.","journal-title":"Nat Biotechnol"},{"key":"1780_CR101","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jconrel.2008.07.021","volume":"131","author":"F Li","year":"2008","unstructured":"Li F, Sun JY, Wang JY, Du SL, Lu WY, Liu M, et al. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Controll Release: Off J Controll Release Soc. 2008;131:77\u201382.","journal-title":"J Controll Release: Off J Controll Release Soc"},{"key":"1780_CR102","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1124\/jpet.106.117945","volume":"321","author":"JE Adrian","year":"2007","unstructured":"Adrian JE, Poelstra K, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J Pharmacol Exp Ther. 2007;321:536\u201343.","journal-title":"J Pharmacol Exp Ther"},{"key":"1780_CR103","first-page":"2086","volume":"119","author":"BT Kren","year":"2009","unstructured":"Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, et al. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Investig. 2009;119:2086\u201399.","journal-title":"J Clin Investig"},{"key":"1780_CR104","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.biomaterials.2009.12.022","volume":"31","author":"F Suriano","year":"2010","unstructured":"Suriano F, Pratt R, Tan JP, Wiradharma N, Nelson A, Yang YY, et al. Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery. Biomaterials. 2010;31:2637\u201345.","journal-title":"Biomaterials"},{"key":"1780_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ijbiomac.2009.11.008","volume":"46","author":"Y Cao","year":"2010","unstructured":"Cao Y, Gu Y, Ma H, Bai J, Liu L, Zhao P, et al. Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharide-doxorubicin conjugate loaded doxorubicin. Int J Biol Macromol. 2010;46:245\u20139.","journal-title":"Int J Biol Macromol"},{"key":"1780_CR106","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jconrel.2008.01.021","volume":"128","author":"YC Wang","year":"2008","unstructured":"Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Controll Release\u202f: Off J Controll Release Soc. 2008;128:32\u201340.","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"1780_CR107","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/jgm.1273","volume":"11","author":"S Diez","year":"2009","unstructured":"Diez S, Navarro G, de ILarduya CT. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med. 2009;11:38\u201345.","journal-title":"J Gene Med"},{"key":"1780_CR108","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.3748\/wjg.v11.i32.4947","volume":"11","author":"XR Qi","year":"2005","unstructured":"Qi XR, Yan WW, Shi J. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol. World J Gastroenterol. 2005;11:4947\u201352.","journal-title":"World J Gastroenterol"},{"key":"1780_CR109","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.gt.3302917","volume":"14","author":"KS Kim","year":"2007","unstructured":"Kim KS, Lei Y, Stolz DB, Liu D. Bifunctional compounds for targeted hepatic gene delivery. Gene Ther. 2007;14:704\u20138.","journal-title":"Gene Ther"},{"key":"1780_CR110","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ejpb.2007.07.005","volume":"68","author":"M Feng","year":"2008","unstructured":"Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2008;68:688\u201393.","journal-title":"Eur J Pharm Biopharm: Off J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"key":"1780_CR111","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijpharm.2009.01.009","volume":"372","author":"SJ Cheong","year":"2009","unstructured":"Cheong SJ, Lee CM, Kim SL, Jeong HJ, Kim EM, Park EH, et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system. Int J Pharm. 2009;372:169\u201376.","journal-title":"Int J Pharm"},{"key":"1780_CR112","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijpharm.2008.12.021","volume":"371","author":"CM Lee","year":"2009","unstructured":"Lee CM, Jeong HJ, Kim SL, Kim EM, Kim DW, Lim ST, et al. SPION-loaded chitosan-linoleic acid nanoparticles to target hepatocytes. Int J Pharm. 2009;371:163\u20139.","journal-title":"Int J Pharm"},{"key":"1780_CR113","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijpharm.2009.07.030","volume":"382","author":"KJ Longmuir","year":"2009","unstructured":"Longmuir KJ, Haynes SM, Baratta JL, Kasabwalla N, Robertson RT. Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm. 2009;382:222\u201333.","journal-title":"Int J Pharm"},{"key":"1780_CR114","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2004.02.003","volume":"96","author":"HS Yoo","year":"2004","unstructured":"Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96:273\u201383.","journal-title":"J Control Release"},{"key":"1780_CR115","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/ar7000815","volume":"41","author":"PS Low","year":"2008","unstructured":"Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res. 2008;41:120\u20139.","journal-title":"Acc Chem Res"},{"key":"1780_CR116","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nrc3912","volume":"15","author":"CY Lin","year":"2015","unstructured":"Lin CY, Gustafsson JA. Targeting liver X receptors in cancer therapeutics. Nat Rev Cancer. 2015;15:216\u201324.","journal-title":"Nat Rev Cancer"},{"key":"1780_CR117","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm828","volume":"9","author":"E Song","year":"2003","unstructured":"Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347\u201351.","journal-title":"Nat Med"},{"key":"1780_CR118","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7150\/jca.7279","volume":"4","author":"H Nishikawa","year":"2013","unstructured":"Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer. 2013;4:635\u201343.","journal-title":"J Cancer"},{"key":"1780_CR119","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.cyto.2013.09.009","volume":"64","author":"J Zhao","year":"2013","unstructured":"Zhao J, Lawless MW. Stop feeding cancer: pro-inflammatory role of visceral adiposity in liver cancer. Cytokine. 2013;64:626\u201337.","journal-title":"Cytokine"},{"key":"1780_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-013-1772-5","volume":"15","author":"A Jain","year":"2013","unstructured":"Jain A, Gulbake A, Jain A, Shilpi S, Hurkat P, Jain SK. Dual drug delivery using \u201csmart\u201d liposomes for triggered release of anticancer agents. J Nanopart Res. 2013;15:1\u201312.","journal-title":"J Nanopart Res"},{"key":"1780_CR121","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005678","volume":"30","author":"A Jain","year":"2013","unstructured":"Jain A, Gulbake A, Shilpi S, Jain A, Hurkat P, Jain SK. A new horizon in modifications of chitosan: syntheses and applications. Crit Rev Ther Drug Carrier Syst. 2013;30:91\u2013181.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1780_CR122","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2353\/ajpath.2010.090136","volume":"176","author":"F Jacobs","year":"2010","unstructured":"Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol. 2010;176:14\u201321.","journal-title":"Am J Pathol"},{"key":"1780_CR123","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.actbio.2009.07.002","volume":"6","author":"X Li","year":"2010","unstructured":"Li X, Guo H, Wang J, Wu Q, Lin X. Fabrication of novel hepatoma-targeting microdisks by hydrogen bond-assisted self-assembly of an azacitidine-conjugating amphiphilic random copolymer. Acta Biomater. 2010;6:511\u20138.","journal-title":"Acta Biomater"},{"key":"1780_CR124","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/molecules27031062","volume":"27","author":"S Cannito","year":"2022","unstructured":"Cannito S, Bincoletto V, Turato C, Pontisso P, Scupoli MT, Ailuno G, et al. Hyaluronated and PEGylated liposomes as a potential drug-delivery strategy to specifically target liver cancer and inflammatory cells. Molecules. 2022;27:1062.","journal-title":"Molecules"},{"key":"1780_CR125","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.bi.51.070182.002531","volume":"51","author":"G Ashwell","year":"1982","unstructured":"Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem. 1982;51:531\u201354.","journal-title":"Annu Rev Biochem"},{"key":"1780_CR126","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1242\/dev.132209","volume":"143","author":"DT Peters","year":"2016","unstructured":"Peters DT, Henderson CA, Warren CR, Friesen M, Xia F, Becker CE, et al. Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells. Development. 2016;143:1475\u201381.","journal-title":"Development"},{"key":"1780_CR127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0006-2952(97)00223-2","volume":"54","author":"G Di Stefano","year":"1997","unstructured":"Di Stefano G, Colonna FP, Bongini A, Busi C, Mattioli A, Fiume L. Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem Pharmacol. 1997;54:357\u201363.","journal-title":"Biochem Pharmacol"},{"key":"1780_CR128","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1478-3231.2006.01289.x","volume":"26","author":"G Di Stefano","year":"2006","unstructured":"Di Stefano G, Fiume L, Baglioni M, Bolondi L, Busi C, Chieco P, et al. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int: Off J Int Assoc Study Liver. 2006;26:726\u201333.","journal-title":"Liver Int: Off J Int Assoc Study Liver"},{"key":"1780_CR129","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jhep.2005.02.045","volume":"43","author":"L Fiume","year":"2005","unstructured":"Fiume L, Bolondi L, Busi C, Chieco P, Kratz F, Lanza M, et al. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J Hepatol. 2005;43:645\u201352.","journal-title":"J Hepatol"},{"key":"1780_CR130","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2009.05.007","volume":"61","author":"R Duncan","year":"2009","unstructured":"Duncan R. Development of HPMA copolymer\u2013anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009;61:1131\u201348.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR131","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1567201043479939","volume":"1","author":"Y-T Wu","year":"2004","unstructured":"Wu Y-T, Jiaang W-T, Lin K-G, Huang C-M, Chang C-H, Sun Y-L, et al. A new N-acetylgalactosamine containing peptide as a targeting vehicle for mammalian hepatocytes via asialoglycoprotein receptor endocytosis. Curr Drug Deliv. 2004;1:119\u201327.","journal-title":"Curr Drug Deliv"},{"key":"1780_CR132","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1021\/bc100346n","volume":"21","author":"L Zhu","year":"2010","unstructured":"Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem. 2010;21:2119\u201327.","journal-title":"Bioconjug Chem"},{"key":"1780_CR133","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/0885328210364678","volume":"26","author":"C Nie","year":"2011","unstructured":"Nie C, Liu C, Chen G, Dai J, Li H, Shuai X. Hepatocyte-targeted psi RNA Delivery Mediated by Galactosylated Poly (Ethylene Glycol)-Graft-Polyethylenimine In Vitro. Journal of biomaterials applications. 2011;26:255\u201375. https:\/\/doi.org\/10.1177\/0885328210364678.","journal-title":"Journal of biomaterials applications."},{"key":"1780_CR134","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","volume":"203","author":"AA D'Souza","year":"2015","unstructured":"D\u2019Souza AA, Devarajan PV. Asialoglycoprotein receptor mediated hepatocyte targeting\u2014Strategies and applications. J Control Release. 2015;203:126\u201339.","journal-title":"J Control Release"},{"key":"1780_CR135","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/02652048.2013.879929","volume":"31","author":"R Dangi","year":"2014","unstructured":"Dangi R, Hurkat P, Jain A, Shilpi S, Jain A, Gulbake A, et al. Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. J Microencapsul. 2014;31:479\u201387.","journal-title":"J Microencapsul"},{"key":"1780_CR136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/jps.23344","volume":"102","author":"X Zhang","year":"2013","unstructured":"Zhang X, Zhang X, Yu P, Han Y, Li Y, Li C. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system. J Pharm Sci. 2013;102:145\u201353.","journal-title":"J Pharm Sci"},{"key":"1780_CR137","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1023\/A:1018949218380","volume":"11","author":"S Unezaki","year":"1994","unstructured":"Unezaki S, Maruyama K, Takahashi N, Koyama M, Yuda T, Suginaka A, et al. Enhanced delivery and antitumor activity of doxorubicin using long-circulating thermosensitive liposomes containing amphipathic polyethylene glycol in combination with local hyperthermia. Pharm Res. 1994;11:1180\u20135.","journal-title":"Pharm Res"},{"key":"1780_CR138","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1248\/bpb.20.259","volume":"20","author":"N Murahashi","year":"1997","unstructured":"Murahashi N, Ishihara H, Sasaki A, Sakagami M, Hamana H. Hepatic accumulation of glutamic acid branched neogalactosyllipid modified liposomes. Biol Pharm Bull. 1997;20:259\u201366.","journal-title":"Biol Pharm Bull"},{"key":"1780_CR139","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0168-3659(01)00411-4","volume":"75","author":"Y Maitani","year":"2001","unstructured":"Maitani Y, Kawano K, Yamada K, Nagai T, Takayama K. Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells. J Controll Release\u202f: Off J Controll Release Soc. 2001;75:381\u20139.","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"1780_CR140","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/1061186X.2013.860982","volume":"22","author":"P Detampel","year":"2013","unstructured":"Detampel P, Witzigmann D, Kr\u00e4henb\u00fchl S, Huwyler J. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. J Drug Target. 2013;22:232\u201341.","journal-title":"J Drug Target"},{"key":"1780_CR141","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/1061186X.2012.741135","volume":"21","author":"B Guo","year":"2013","unstructured":"Guo B, Cheng Y, Li N, Li X, Jin M, Li T, et al. In vitro and in vivo studies of galactose-modified liver-targeting liposomes. J Drug Target. 2013;21:257\u201364.","journal-title":"J Drug Target"},{"key":"1780_CR142","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1021\/acsomega.2c05976","volume":"8","author":"S Priya","year":"2023","unstructured":"Priya S, Desai VM, Singhvi G. Surface Modification of Lipid-Based Nanocarriers: A Potential Approach to Enhance Targeted Drug Delivery. ACS Omega. 2023;8:74\u201386.","journal-title":"ACS Omega"},{"key":"1780_CR143","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3390\/polym13071027","volume":"13","author":"V De Leo","year":"2021","unstructured":"De Leo V, Milano F, Agostiano A, Catucci L. Recent advancements in polymer\/liposome assembly for drug delivery: from surface modifications to hybrid vesicles. Polymers. 2021;13:1027.","journal-title":"Polymers"},{"key":"1780_CR144","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1359-6446(05)03383-0","volume":"10","author":"MR Redinbo","year":"2005","unstructured":"Redinbo MR, Potter PM. Mammalian carboxylesterases: from drug targets to protein therapeutics. Drug Discovery Today. 2005;10:313\u201325.","journal-title":"Drug Discovery Today"},{"key":"1780_CR145","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.pharmtox.38.1.257","volume":"38","author":"T Satoh","year":"1998","unstructured":"Satoh T, Hosokawa M. The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol. 1998;38:257\u201388.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1780_CR146","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.abb.2012.04.010","volume":"522","author":"MK Ross","year":"2012","unstructured":"Ross MK, Borazjani A, Wang R, Crow JA, Xie S. Examination of the carboxylesterase phenotype in human liver. Arch Biochem Biophys. 2012;522:44\u201356.","journal-title":"Arch Biochem Biophys"},{"key":"1780_CR147","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/molecules13020412","volume":"13","author":"M Hosokawa","year":"2008","unstructured":"Hosokawa M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules. 2008;13:412\u201331.","journal-title":"Molecules"},{"key":"1780_CR148","first-page":"834","volume":"2","author":"C Ramaa","year":"2010","unstructured":"Ramaa C, Tilekar K, Patil V. Liver cancer: different approaches for targeting. Int J PharmTech Res. 2010;2:834\u201342.","journal-title":"Int J PharmTech Res"},{"key":"1780_CR149","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1158\/1078-0432.CCR-12-1184","volume":"19","author":"SE Pratt","year":"2013","unstructured":"Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013;19:1159\u201368.","journal-title":"Clin Cancer Res"},{"key":"1780_CR150","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cmet.2016.05.005","volume":"24","author":"A Wahlstr\u00f6m","year":"2016","unstructured":"Wahlstr\u00f6m A, Sayin SI, Marschall H-U, B\u00e4ckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41\u201350.","journal-title":"Cell Metab"},{"key":"1780_CR151","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17425247.2016.1178233","volume":"13","author":"C Faustino","year":"2016","unstructured":"Faustino C, Serafim C, Rijo P, Reis CP. Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents. Expert Opin Drug Deliv. 2016;13:1133\u201348.","journal-title":"Expert Opin Drug Deliv"},{"key":"1780_CR152","first-page":"853","volume":"61","author":"O Briz","year":"2002","unstructured":"Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, et al. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol. 2002;61:853\u201360.","journal-title":"Mol Pharmacol"},{"key":"1780_CR153","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/aps.2011.7","volume":"32","author":"DQ Chen","year":"2011","unstructured":"Chen DQ, Wang X, Chen L, He JX, Miao ZH, Shen JK. Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. Acta Pharmacol Sin. 2011;32:664\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"1780_CR154","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132:171\u201383.","journal-title":"J Control Release"},{"key":"1780_CR155","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","volume":"63","author":"S Acharya","year":"2011","unstructured":"Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63:170\u201383.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR156","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","volume":"71","author":"H Maeda","year":"2009","unstructured":"Maeda H, Bharate G, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409\u201319.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"1780_CR157","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/9781119041450.ch4","volume":"28","author":"A Jain","year":"2015","unstructured":"Jain A, Jain SK. Environmentally Responsive Chitosan-Based Nanocarriers (CBNs). Handbook of polymers for pharmaceutical technologies: Biodegradable polymers. 2015;28(3):105\u201325. https:\/\/doi.org\/10.1002\/9781119041450.ch4.","journal-title":"Handbook of polymers for pharmaceutical technologies: Biodegradable polymers."},{"key":"1780_CR158","first-page":"1","volume":"4","author":"A Jain","year":"2013","unstructured":"Jain A, Jain SK. Engineered chitosan: A potential tool in biomedical applications. Int J Biotechnol Bioeng Res. 2013;4:1\u20134.","journal-title":"Int J Biotechnol Bioeng Res"},{"key":"1780_CR159","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13277-014-2855-3","volume":"36","author":"JJ Yan","year":"2015","unstructured":"Yan JJ, Liao JZ, Lin JS, He XX. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems. Tumour Biol. 2015;36:55\u201367.","journal-title":"Tumour Biol"},{"key":"1780_CR160","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1053\/j.gastro.2004.09.037","volume":"127","author":"L Mohr","year":"2004","unstructured":"Mohr L, Yeung A, Aloman C, Wittrup D, Wands JR. Antibody-directed therapy for human hepatocellular carcinoma. Gastroenterology. 2004;127:S225\u201331.","journal-title":"Gastroenterology"},{"key":"1780_CR161","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(09)70330-4","volume":"11","author":"G Folprecht","year":"2010","unstructured":"Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38\u201347.","journal-title":"Lancet Oncol"},{"key":"1780_CR162","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/hep.27863","volume":"62","author":"NA Timchenko","year":"2015","unstructured":"Timchenko NA. Cell-type specific functions of epidermal growth factor receptor are involved in development of hepatocellular carcinoma. Hepatology. 2015;62:314\u20136.","journal-title":"Hepatology"},{"key":"1780_CR163","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1515\/ejnm-2014-0042","volume":"6","author":"CA Monnier","year":"2014","unstructured":"Monnier CA, Burnand D, Rothen-Rutishauser B, Lattuada M, Petri-Fink A. Magnetoliposomes: opportunities and challenges. Eur J Nanomed. 2014;6:201\u201315.","journal-title":"Eur J Nanomed"},{"key":"1780_CR164","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2217\/nnm.11.14","volume":"6","author":"H Fattahi","year":"2011","unstructured":"Fattahi H, Laurent S, Liu F, Arsalani N, Vander Elst L, Muller RN. Magnetoliposomes as multimodal contrast agents for molecular imaging and cancer nanotheragnostics. Nanomedicine (Lond). 2011;6:529\u201344.","journal-title":"Nanomedicine (Lond)"},{"key":"1780_CR165","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/0024-3205(96)00220-2","volume":"58","author":"E Viroonchatapan","year":"1996","unstructured":"Viroonchatapan E, Sato H, Ueno M, Adachi I, Tazawa K, Horikoshi I. Magnetic targeting of thermosensittve magnetoliposomes to mouse livers in an< i> in situ<\/i> on-line perfusion system. Life Sci. 1996;58:2251\u201361.","journal-title":"Life Sci"},{"key":"1780_CR166","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.biomaterials.2010.11.005","volume":"32","author":"SJ Soenen","year":"2011","unstructured":"Soenen SJ, Brisson AR, Jonckheere E, Nuytten N, Tan S, Himmelreich U, et al. The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes. Biomaterials. 2011;32:1748\u201358.","journal-title":"Biomaterials"},{"key":"1780_CR167","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1016\/j.biomaterials.2010.02.068","volume":"31","author":"JH Maeng","year":"2010","unstructured":"Maeng JH, Lee DH, Jung KH, Bae YH, Park IS, Jeong S, et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials. 2010;31:4995\u20135006.","journal-title":"Biomaterials"},{"key":"1780_CR168","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/17425247.2021.1915983","volume":"18","author":"SRS Veloso","year":"2021","unstructured":"Veloso SRS, Andrade RGD, Castanheira EMS. Magnetoliposomes: recent advances in the field of controlled drug delivery. Expert Opin Drug Deliv. 2021;18:1323\u201334.","journal-title":"Expert Opin Drug Deliv"},{"key":"1780_CR169","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature01250","volume":"421","author":"LO Martinez","year":"2003","unstructured":"Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003;421:75\u20139.","journal-title":"Nature"},{"key":"1780_CR170","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0079-6700(03)00015-7","volume":"28","author":"G Riess","year":"2003","unstructured":"Riess G. Micellization of block copolymers. Prog Polym Sci. 2003;28:1107\u201370.","journal-title":"Prog Polym Sci"},{"key":"1780_CR171","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nrc1566","volume":"5","author":"M Ferrari","year":"2005","unstructured":"Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161\u201371.","journal-title":"Nat Rev Cancer"},{"key":"1780_CR172","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrc903","volume":"2","author":"TM Allen","year":"2002","unstructured":"Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750\u201363.","journal-title":"Nat Rev Cancer"},{"key":"1780_CR173","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/jbm.a.31181","volume":"84","author":"ZF Gan","year":"2008","unstructured":"Gan ZF, Jiang JS, Yang Y, Du B, Qian M, Zhang P. Immobilization of homing peptide on magnetite nanoparticles and its specificity in vitro. J Biomed Mater Res A. 2008;84:10\u20138.","journal-title":"J Biomed Mater Res A"},{"key":"1780_CR174","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.actbio.2007.06.006","volume":"4","author":"J Zhang","year":"2008","unstructured":"Zhang J, Rana S, Srivastava R, Misra R. On the chemical synthesis and drug delivery response of folate receptor-activated, polyethylene glycol-functionalized magnetite nanoparticles. Acta Biomater. 2008;4:40\u20138.","journal-title":"Acta Biomater"},{"key":"1780_CR175","first-page":"321","volume":"17","author":"A Jain","year":"2017","unstructured":"Jain A, Tiwari A, Verma A, Jain SK. Vitamins for cancer prevention and treatment: an insight. Curr Mol Med. 2017;17:321\u201340.","journal-title":"Curr Mol Med"},{"key":"1780_CR176","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijpharm.2008.03.039","volume":"359","author":"A Lin","year":"2008","unstructured":"Lin A, Liu Y, Huang Y, Sun J, Wu Z, Zhang X, et al. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharm. 2008;359:247\u201353.","journal-title":"Int J Pharm"},{"key":"1780_CR177","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.510270319","volume":"27","author":"J Wu","year":"1998","unstructured":"Wu J, Liu P, Zhu JL, Maddukuri S, Zern MA. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology. 1998;27:772\u20138.","journal-title":"Hepatology"},{"key":"1780_CR178","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1016\/j.actbio.2010.04.021","volume":"6","author":"W Huang","year":"2010","unstructured":"Huang W, Wang W, Wang P, Tian Q, Zhang C, Wang C, et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Acta Biomater. 2010;6:3927\u201335.","journal-title":"Acta Biomater"},{"key":"1780_CR179","doi-asserted-by":"crossref","unstructured":"Ma Pa, Liu S, Huang Y, Chen X, Zhang L, Jing X. Lactose mediated liver-targeting effect observed by< i> ex vivo<\/i> imaging technology. Biomaterials. 2010;31:2646-54.","DOI":"10.1016\/j.biomaterials.2009.12.019"},{"key":"1780_CR180","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1039\/c3tb21709d","volume":"2","author":"L Yang","year":"2014","unstructured":"Yang L, Xiao H, Yan L, Wang R, Huang Y, Xie Z, et al. Lactose targeting oxaliplatin prodrug loaded micelles for more effective chemotherapy of hepatocellular carcinoma. J Mater Chem B. 2014;2:2097\u2013106.","journal-title":"J Mater Chem B"},{"key":"1780_CR181","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3390\/pharmaceutics14081636","volume":"14","author":"S Kotta","year":"2022","unstructured":"Kotta S, Aldawsari HM, Badr-Eldin SM, Nair AB, Yt K. Progress in polymeric micelles for drug delivery applications. Pharmaceutics. 2022;14:1636.","journal-title":"Pharmaceutics"},{"key":"1780_CR182","doi-asserted-by":"publisher","unstructured":"Bishnoi M, Jain A, Hurkat P, Jain SK. Chondroitin sulphate: a focus on osteoarthritis. Glycoconjugate J. 2016:1\u201313. https:\/\/doi.org\/10.1007\/s10719-016-9665-3","DOI":"10.1007\/s10719-016-9665-3"},{"key":"1780_CR183","doi-asserted-by":"publisher","first-page":"C14","DOI":"10.1016\/0008-6215(85)85175-2","volume":"137","author":"S Hanessian","year":"1985","unstructured":"Hanessian S, Hoornaert C, Pernet AG, Nadzan AM. Design and synthesis of potential megacaloric parenteral nutrients. Carbohyd Res. 1985;137:C14\u20136.","journal-title":"Carbohyd Res"},{"key":"1780_CR184","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10967-013-2502-2","volume":"298","author":"ALB de Barros","year":"2013","unstructured":"de Barros ALB, de Andrade SF, de Souza Filho JD, Cardoso VN, Alves RJ. Radiolabeling of low molecular weight d-galactose-based glycodendrimer with technetium-99m and biodistribution studies. J Radioanal Nucl Chem. 2013;298:605\u20139.","journal-title":"J Radioanal Nucl Chem"},{"key":"1780_CR185","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/pharmaceutics14061292","volume":"14","author":"X Li","year":"2022","unstructured":"Li X, Naeem A, Xiao S, Hu L, Zhang J, Zheng Q. Safety challenges and application strategies for the use of dendrimers in medicine. Pharmaceutics. 2022;14:1292.","journal-title":"Pharmaceutics"},{"key":"1780_CR186","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.canlet.2005.01.024","volume":"231","author":"J Chen","year":"2006","unstructured":"Chen J, Wu H, Han DY, Xie CS. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett. 2006;231:169\u201375.","journal-title":"Cancer Lett"},{"key":"1780_CR187","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/hep.510280111","volume":"28","author":"R Yamaguchi","year":"1998","unstructured":"Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28:68\u201377.","journal-title":"Hepatology"},{"key":"1780_CR188","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406\u201317.","journal-title":"Cancer Discov"},{"key":"1780_CR189","doi-asserted-by":"publisher","first-page":"106413","DOI":"10.1016\/j.jddst.2024.106413","volume":"102","author":"S Jain","year":"2024","unstructured":"Jain S, Bhushan B, Mishra AK, Singh R. Unlocking therapeutic potential of siRNA-based drug delivery system for treatment of Alzheimer\u2019s disease. J Drug Deliv Sci Technol. 2024;102:106413.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1780_CR190","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3390\/ijms22041631","volume":"22","author":"HO Alsaab","year":"2021","unstructured":"Alsaab HO, Al-Hibs AS, Alzhrani R, Alrabighi KK, Alqathama A, Alwithenani A, et al. Nanomaterials for antiangiogenic therapies for cancer: a promising tool for personalized medicine. Int J Mol Sci. 2021;22:1631.","journal-title":"Int J Mol Sci"},{"key":"1780_CR191","doi-asserted-by":"publisher","first-page":"14547","DOI":"10.1073\/pnas.94.26.14547","volume":"94","author":"T Hara","year":"1997","unstructured":"Hara T, Tan Y, Huang L. gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. P Natl Acad Sci USA. 1997;94:14547\u201352.","journal-title":"P Natl Acad Sci USA"},{"key":"1780_CR192","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1016\/S0021-9258(19)70811-4","volume":"255","author":"E Windler","year":"1980","unstructured":"Windler E, Chao Y-S, Havel R. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem. 1980;255:5475\u201380.","journal-title":"J Biol Chem"},{"key":"1780_CR193","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2005.07.015","volume":"303","author":"AM Dierling","year":"2005","unstructured":"Dierling AM, Cui Z. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int J Pharm. 2005;303:143\u201352.","journal-title":"Int J Pharm"},{"key":"1780_CR194","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.addr.2020.08.003","volume":"159","author":"S Busatto","year":"2020","unstructured":"Busatto S, Walker SA, Grayson W, Pham A, Tian M, Nesto N, et al. Lipoprotein-based drug delivery. Adv Drug Deliv Rev. 2020;159:377\u201390.","journal-title":"Adv Drug Deliv Rev"},{"key":"1780_CR195","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijpharm.2009.08.001","volume":"381","author":"S Tamilvanan","year":"2009","unstructured":"Tamilvanan S. Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body. Int J Pharm. 2009;381:62\u201376.","journal-title":"Int J Pharm"},{"key":"1780_CR196","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/9783527650002.ch4","volume":"2","author":"B Valeur","year":"2012","unstructured":"Valeur B, Berberan-Santos MN. Structural Effects on Fluorescence Emission. Mol Fluoresc. 2012;2:75\u2013105. https:\/\/doi.org\/10.1002\/9783527650002.ch4.","journal-title":"Mol Fluoresc."},{"key":"1780_CR197","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1021\/nl071546n","volume":"7","author":"V Bagalkot","year":"2007","unstructured":"Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7:3065\u201370.","journal-title":"Nano Lett"},{"key":"1780_CR198","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/ja807711w","volume":"131","author":"R Kikkeri","year":"2009","unstructured":"Kikkeri R, Lepenies B, Adibekian A, Laurino P, Seeberger PH. In vitro imaging and in vivo liver targeting with carbohydrate capped quantum dots. J Am Chem Soc. 2009;131:2110\u20132.","journal-title":"J Am Chem Soc"},{"key":"1780_CR199","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jat.4083","volume":"41","author":"X Huang","year":"2021","unstructured":"Huang X, Tang M. Research advance on cell imaging and cytotoxicity of different types of quantum Dots. J Appl Toxicol. 2021;41:342\u201361.","journal-title":"J Appl Toxicol"},{"key":"1780_CR200","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/2051013614541440","volume":"2","author":"RA Schwendener","year":"2014","unstructured":"Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014;2:159\u201382.","journal-title":"Ther Adv Vaccines"},{"key":"1780_CR201","doi-asserted-by":"publisher","unstructured":"Saunders KO, Edwards RJ, Tilahun K, Manne K, Lu X, Cain DW, Wiehe K, Williams WB, Mansouri K, Hernandez GE, Sutherland L. Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection. Science translational medicine. 2022;14(661):eabo5598. https:\/\/doi.org\/10.1126\/scitranslmed.abo5598.","DOI":"10.1126\/scitranslmed.abo5598"},{"key":"1780_CR202","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/sj.cgt.7700400","volume":"9","author":"X Liu","year":"2002","unstructured":"Liu X, Tian P, Yu Y, Yao M, Cao X, Gu J. Enhanced antitumor effect of EGF R-targeted p21WAF-1 and GM-CSF gene transfer in the established murine hepatoma by peritumoral injection. Cancer Gene Ther. 2002;9:100\u20138.","journal-title":"Cancer Gene Ther"},{"key":"1780_CR203","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1053\/jhep.2002.36372","volume":"36","author":"MF Wolschek","year":"2002","unstructured":"Wolschek MF, Thallinger C, Kursa M, Rossler V, Allen M, Lichtenberger C, et al. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology. 2002;36:1106\u201314.","journal-title":"Hepatology"},{"key":"1780_CR204","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1093\/nar\/28.14.2717","volume":"28","author":"MK Bijsterbosch","year":"2000","unstructured":"Bijsterbosch MK, Rump ET, De Vrueh RL, Dorland R, van Veghel R, Tivel KL, et al. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res. 2000;28:2717\u201325.","journal-title":"Nucleic Acids Res"},{"key":"1780_CR205","doi-asserted-by":"publisher","first-page":"e99272","DOI":"10.1371\/journal.pone.0099272","volume":"9","author":"R Gedaly","year":"2014","unstructured":"Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, et al. Targeting the Wnt\/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS ONE. 2014;9:e99272.","journal-title":"PLoS ONE"},{"key":"1780_CR206","doi-asserted-by":"publisher","first-page":"102667","DOI":"10.1016\/j.nano.2023.102667","volume":"50","author":"S Ellipilli","year":"2023","unstructured":"Ellipilli S, Wang H, Binzel DW, Shu D, Guo P. Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer regression. Nanomed: Nanotechnol Biol Med. 2023;50:102667.","journal-title":"Nanomed: Nanotechnol Biol Med"},{"key":"1780_CR207","first-page":"3395","volume":"15","author":"Z Xiao","year":"2018","unstructured":"Xiao Z, Shen J, Zhang L, Li M, Hu W, Cho C. Therapeutic targeting of noncoding RNAs in hepatocellular carcinoma: Recent progress and future prospects. Oncol Lett. 2018;15:3395\u2013402.","journal-title":"Oncol Lett"},{"key":"1780_CR208","first-page":"35","volume":"1","author":"L Quagliata","year":"2014","unstructured":"Quagliata L, Terracciano LM. Liver diseases and long non-coding rnas: new insight and perspective. Front Med (Lausanne). 2014;1:35.","journal-title":"Front Med (Lausanne)"},{"key":"1780_CR209","first-page":"1073","volume":"12","author":"C Braconi","year":"2012","unstructured":"Braconi C, Patel T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets. 2012;12:1073\u201380.","journal-title":"Curr Cancer Drug Targets"},{"key":"1780_CR210","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/hep.26195","volume":"57","author":"JF Huang","year":"2013","unstructured":"Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN, et al. Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology. 2013;57:1882\u201392.","journal-title":"Hepatology"},{"key":"1780_CR211","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1423-0127-16-30","volume":"16","author":"P Matar","year":"2009","unstructured":"Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, et al. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30.","journal-title":"J Biomed Sci"},{"key":"1780_CR212","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11010-017-3092-z","volume":"437","author":"V Rai","year":"2018","unstructured":"Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem. 2018;437:13\u201336.","journal-title":"Mol Cell Biochem"},{"key":"1780_CR213","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1159\/000341702","volume":"30","author":"V Wieser","year":"2012","unstructured":"Wieser V, Moschen AR, Tilg H. Adipocytokines and hepatocellular carcinoma. Dig Dis. 2012;30:508\u201313.","journal-title":"Dig Dis"},{"key":"1780_CR214","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/hep.26007","volume":"56","author":"K Wu","year":"2012","unstructured":"Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, et al. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology. 2012;56:2255\u201367.","journal-title":"Hepatology"},{"key":"1780_CR215","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/11595360-000000000-00000","volume":"25","author":"M Ho","year":"2011","unstructured":"Ho M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs\u202f: Clin Immunother Biopharm Gene Ther. 2011;25:275\u201384.","journal-title":"BioDrugs : Clin Immunother Biopharm Gene Ther"},{"key":"1780_CR216","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1586\/egh.10.18","volume":"4","author":"F Korangy","year":"2010","unstructured":"Korangy F, Hochst B, Manns MP, Greten TF. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2010;4:345\u201353.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1780_CR217","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1002\/ijc.27473","volume":"131","author":"M Malz","year":"2012","unstructured":"Malz M, Aulmann A, Samarin J, Bissinger M, Longerich T, Schmitt S, et al. Nuclear accumulation of seven in absentia homologue-2 supports motility and proliferation of liver cancer cells. Int J Cancer J Int du Cancer. 2012;131:2016\u201326.","journal-title":"Int J Cancer J Int du Cancer"},{"key":"1780_CR218","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1038\/ncomms7536","volume":"6","author":"W Gao","year":"2015","unstructured":"Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015;6:6536.","journal-title":"Nat Commun"},{"key":"1780_CR219","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jconrel.2005.12.010","volume":"111","author":"T Gonzalo","year":"2006","unstructured":"Gonzalo T, Talman EG, van de Ven A, Temming K, Greupink R, Beljaars L, et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Controll Release\u202f: Off J Controll Release Soc. 2006;111:193\u2013203.","journal-title":"J Controll Release : Off J Controll Release Soc"},{"key":"1780_CR220","doi-asserted-by":"crossref","unstructured":"Hermanson GT. Chapter 22-Preparation of Liposome Conjugates and Derivatives. Bioconjugate techniques. Academic press; 2013. pp. 858\u201399.","DOI":"10.1016\/B978-0-12-370501-3.00022-9"},{"key":"1780_CR221","doi-asserted-by":"publisher","first-page":"17438","DOI":"10.1073\/pnas.1312649110","volume":"110","author":"A Furukawa","year":"2013","unstructured":"Furukawa A, Kamishikiryo J, Mori D, Toyonaga K, Okabe Y, Toji A, et al. Structural analysis for glycolipid recognition by the C-type lectins Mincle and MCL. Proc Natl Acad Sci U S A. 2013;110:17438\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1780_CR222","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.biomaterials.2012.09.049","volume":"34","author":"Y He","year":"2013","unstructured":"He Y, Cheng G, Xie L, Nie Y, He B, Gu Z. Polyethyleneimine\/DNA polyplexes with reduction-sensitive hyaluronic acid derivatives shielding for targeted gene delivery. Biomaterials. 2013;34:1235\u201345.","journal-title":"Biomaterials"},{"key":"1780_CR223","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007419","volume":"30","author":"M Hamidi","year":"2013","unstructured":"Hamidi M, Azadi A, Rafiei P, Ashrafi H. A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Crit Rev Ther Drug Carrier Syst. 2013;30:435\u201367.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"1780_CR224","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2011.07.013","volume":"427","author":"T Wang","year":"2012","unstructured":"Wang T, Upponi JR, Torchilin VP. Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm. 2012;427:3\u201320.","journal-title":"Int J Pharm"},{"key":"1780_CR225","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.bbapap.2011.08.016","volume":"1824","author":"U Repnik","year":"2012","unstructured":"Repnik U, Stoka V, Turk V, Turk B. Lysosomes and lysosomal cathepsins in cell death. Biochim Biophys Acta. 2012;1824:22\u201333.","journal-title":"Biochim Biophys Acta"},{"key":"1780_CR226","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.biomaterials.2005.10.027","volume":"27","author":"HF Liang","year":"2006","unstructured":"Liang HF, Chen CT, Chen SC, Kulkarni AR, Chiu YL, Chen MC, et al. Paclitaxel-loaded poly(\u03b3-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials. 2006;27:2051\u20139.","journal-title":"Biomaterials"},{"key":"1780_CR227","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.biomaterials.2008.09.014","volume":"30","author":"Z Xu","year":"2009","unstructured":"Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30:226\u201332.","journal-title":"Biomaterials"},{"key":"1780_CR228","doi-asserted-by":"publisher","first-page":"e47115","DOI":"10.1371\/journal.pone.0047115","volume":"7","author":"M Cheng","year":"2012","unstructured":"Cheng M, He B, Wan T, Zhu W, Han J, Zha B, et al. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. PLoS ONE. 2012;7:e47115.","journal-title":"PLoS ONE"},{"key":"1780_CR229","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21161","volume":"62","author":"M Maluccio","year":"2012","unstructured":"Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012;62:394\u20139.","journal-title":"CA Cancer J Clin"},{"key":"1780_CR230","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrgastro.2009.202","volume":"7","author":"JL Raoul","year":"2010","unstructured":"Raoul JL, Boucher E, Rolland Y, Garin E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol. 2010;7:41\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1780_CR231","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4252\/wjsc.v7.i2.418","volume":"7","author":"IS Song","year":"2015","unstructured":"Song IS, Jeong JY, Jeong SH, Kim HK, Ko KS, Rhee BD, et al. Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells. 2015;7:418\u201327.","journal-title":"World J Stem Cells"},{"key":"1780_CR232","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/hep.24762","volume":"55","author":"CB Rountree","year":"2012","unstructured":"Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology. 2012;55:298\u2013306.","journal-title":"Hepatology"},{"key":"1780_CR233","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.stem.2013.10.001","volume":"14","author":"H Xie","year":"2014","unstructured":"Xie H, Xu J, Hsu JH, Nguyen M, Fujiwara Y, Peng C, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell. 2014;14:68\u201380.","journal-title":"Cell Stem Cell"},{"key":"1780_CR234","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/cgt.2013.6","volume":"20","author":"JY Shin","year":"2013","unstructured":"Shin JY, Chung YS, Kang B, Jiang HL, Yu DY, Han K, et al. Co-delivery of LETM1 and CTMP synergistically inhibits tumor growth in H-ras12V liver cancer model mice. Cancer Gene Ther. 2013;20:186\u201394.","journal-title":"Cancer Gene Ther"},{"key":"1780_CR235","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/febs.12126","volume":"280","author":"J Filmus","year":"2013","unstructured":"Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013;280:2471\u20136.","journal-title":"FEBS J"},{"key":"1780_CR236","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.smim.2017.09.004","volume":"34","author":"FT Andon","year":"2017","unstructured":"Andon FT, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso MJ, et al. Targeting tumor associated macrophages: The new challenge for nanomedicine. Semin Immunol. 2017;34:103\u201313.","journal-title":"Semin Immunol"},{"key":"1780_CR237","doi-asserted-by":"publisher","first-page":"149","DOI":"10.17980\/2015.149","volume":"1","author":"G Marelli","year":"2015","unstructured":"Marelli G. Tumor-associated macrophages, multi-tasking cells in the cancer landscape. Cancer Res Front. 2015;1:149\u201361.","journal-title":"Cancer Res Front"},{"key":"1780_CR238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00595-011-0058-8","volume":"42","author":"K Shirabe","year":"2012","unstructured":"Shirabe K, Mano Y, Muto J, Matono R, Motomura T, Toshima T, et al. Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg Today. 2012;42:1\u20137.","journal-title":"Surg Today"},{"key":"1780_CR239","doi-asserted-by":"publisher","first-page":"e0193015","DOI":"10.1371\/journal.pone.0193015","volume":"13","author":"B Kakoschky","year":"2018","unstructured":"Kakoschky B, Pleli T, Schmithals C, Zeuzem S, Brune B, Vogl TJ, et al. Selective targeting of tumor associated macrophages in different tumor models. PLoS ONE. 2018;13:e0193015.","journal-title":"PLoS ONE"},{"key":"1780_CR240","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nano.2017.12.018","volume":"14","author":"D Cao","year":"2018","unstructured":"Cao D, Liang L, Xu Y, Sun J, Lei M, Wang M, et al. Tumor associated macrophages and angiogenesis dual-recognizable nanoparticles for enhanced cancer chemotherapy. Nanomed: Nanotechnol Biol Med. 2018;14:651\u20139.","journal-title":"Nanomed: Nanotechnol Biol Med"},{"key":"1780_CR241","doi-asserted-by":"publisher","first-page":"597","DOI":"10.4103\/0973-1482.159086","volume":"11","author":"F Wang","year":"2015","unstructured":"Wang F, He Z, Dai W, Li Q, Liu X, Zhang Z, et al. The role of the vascular endothelial growth factor\/vascular endothelial growth factor receptors axis mediated angiogenesis in curcumin-loaded nanostructured lipid carriers induced human HepG2 cells apoptosis. J Cancer Res Ther. 2015;11:597\u2013605.","journal-title":"J Cancer Res Ther"},{"key":"1780_CR242","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/j.1440-1746.2010.06491.x","volume":"26","author":"KZ Qu","year":"2011","unstructured":"Qu KZ, Zhang K, Ma W, Li H, Wang X, Zhang X, et al. Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. J Gastroenterol Hepatol. 2011;26:751\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1780_CR243","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/gt.2011.16","volume":"18","author":"X Cao","year":"2011","unstructured":"Cao X, Yang M, Wei RC, Zeng Y, Gu JF, Huang WD, et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther. 2011;18:765\u201377.","journal-title":"Gene Ther"},{"key":"1780_CR244","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.2174\/092986708785132997","volume":"15","author":"Y Singh","year":"2008","unstructured":"Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008;15:1802\u201326.","journal-title":"Curr Med Chem"},{"key":"1780_CR245","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/auto.26838","volume":"10","author":"XW Liu","year":"2014","unstructured":"Liu XW, Cai TY, Zhu H, Cao J, Su Y, Hu YZ, et al. Q6, a novel hypoxia-targeted drug, regulates hypoxia-inducible factor signaling via an autophagy-dependent mechanism in hepatocellular carcinoma. Autophagy. 2014;10:111\u201322.","journal-title":"Autophagy"},{"key":"1780_CR246","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2174\/156652410791608261","volume":"10","author":"JJ Marin","year":"2010","unstructured":"Marin JJ, Castano B, Blazquez AG, Rosales R, Efferth T, Monte MJ. Strategies for overcoming chemotherapy resistance in enterohepatic tumours. Curr Mol Med. 2010;10:467\u201385.","journal-title":"Curr Mol Med"},{"key":"1780_CR247","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/jpet.104.075903","volume":"312","author":"MD Erion","year":"2005","unstructured":"Erion MD, Van Poelje PD, MacKenna DA, Colby TJ, Montag AC, Fujitaki JM, et al. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther. 2005;312:554\u201360.","journal-title":"J Pharmacol Exp Ther"},{"key":"1780_CR248","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1002\/ijc.26264","volume":"130","author":"T Chiba","year":"2012","unstructured":"Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, et al. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer J Int du cancer. 2012;130:2557\u201367.","journal-title":"Int J Cancer J Int du cancer"},{"key":"1780_CR249","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2174\/156800911796191033","volume":"11","author":"MW Wiedmann","year":"2011","unstructured":"Wiedmann MW, Mossner J. Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. Curr Cancer Drug Targets. 2011;11:714\u201333.","journal-title":"Curr Cancer Drug Targets"},{"key":"1780_CR250","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.phrs.2011.11.011","volume":"65","author":"J Gao","year":"2012","unstructured":"Gao J, Inagaki Y, Song P, Qu X, Kokudo N, Tang W. Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res: Off J Italian Pharmacol Soc. 2012;65:23\u201330.","journal-title":"Pharmacol Res: Off J Italian Pharmacol Soc"},{"key":"1780_CR251","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jhep.2011.05.039","volume":"55","author":"LH Reddy","year":"2011","unstructured":"Reddy LH, Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J Hepatol. 2011;55:1461\u20136.","journal-title":"J Hepatol"},{"key":"1780_CR252","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2217\/nnm.11.79","volume":"6","author":"JPM Almeida","year":"2011","unstructured":"Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine. 2011;6:815\u201335.","journal-title":"Nanomedicine"},{"key":"1780_CR253","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3109\/1061186X.2010.531727","volume":"19","author":"ZJ Chen","year":"2011","unstructured":"Chen ZJ, Yu DX, Liu CX, Yang XY, Zhang N, Ma CH, et al. Gadolinium-conjugated PLA-PEG nanoparticles as liver targeted molecular MRI contrast agent. J Drug Target. 2011;19:657\u201365.","journal-title":"J Drug Target"},{"key":"1780_CR254","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ejrad.2005.11.041","volume":"58","author":"M Kanematsu","year":"2006","unstructured":"Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, et al. Imaging liver metastases: review and update. Eur J Radiol. 2006;58:217\u201328.","journal-title":"Eur J Radiol"},{"key":"1780_CR255","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.eururo.2008.12.034","volume":"55","author":"HC Thoeny","year":"2009","unstructured":"Thoeny HC, Triantafyllou M, Birkhaeuser FD, Froehlich JM, Tshering DW, Binser T, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol. 2009;55:761\u20139.","journal-title":"Eur Urol"},{"key":"1780_CR256","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ejrad.2005.11.040","volume":"58","author":"A Tanimoto","year":"2006","unstructured":"Tanimoto A, Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol. 2006;58:200\u201316.","journal-title":"Eur J Radiol"},{"key":"1780_CR257","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1166\/jnn.2011.3821","volume":"11","author":"JS Lee","year":"2011","unstructured":"Lee JS, Rodriguez-Luccioni HL, Mendez J, Sood AK, Lpez-Berestein G, Rinaldi C, et al. Hyperthermia induced by magnetic nanoparticles improves the effectiveness of the anticancer drug cis-diamminedichloroplatinum. J Nanosci Nanotechnol. 2011;11:4153\u20137.","journal-title":"J Nanosci Nanotechnol"},{"key":"1780_CR258","doi-asserted-by":"publisher","first-page":"11631","DOI":"10.1021\/la903512m","volume":"26","author":"ST Selvan","year":"2009","unstructured":"Selvan ST, Tan TTY, Yi DK, Jana NR. Functional and multifunctional nanoparticles for bioimaging and biosensing. Langmuir. 2009;26:11631\u201341.","journal-title":"Langmuir"},{"key":"1780_CR259","doi-asserted-by":"publisher","first-page":"e49462","DOI":"10.1371\/journal.pone.0049462","volume":"7","author":"SL Anwar","year":"2012","unstructured":"Anwar SL, Krech T, Hasemeier B, Schipper E, Schweitzer N, Vogel A, et al. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS ONE. 2012;7:e49462.","journal-title":"PLoS ONE"},{"key":"1780_CR260","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3892\/or.2012.2141","volume":"29","author":"K Kawai","year":"2013","unstructured":"Kawai K, Tamura K, Sakata I, Ishida J, Nagata M, Tsukada H, et al. A new in vivo model to analyze hepatic metastasis of the human colon cancer cell line HCT116 in NOD\/Shi-scid\/IL-2Rgamma(null) (NOG) mice by (18)F-FDG PET\/CT. Oncol Rep. 2013;29:464\u20138.","journal-title":"Oncol Rep"},{"key":"1780_CR261","doi-asserted-by":"publisher","first-page":"e66416","DOI":"10.1371\/journal.pone.0066416","volume":"8","author":"C Wu","year":"2013","unstructured":"Wu C, Gong F, Pang P, Shen M, Zhu K, Cheng D, et al. An RGD-modified MRI-visible polymeric vector for targeted siRNA delivery to hepatocellular carcinoma in nude mice. PLoS ONE. 2013;8:e66416.","journal-title":"PLoS ONE"},{"key":"1780_CR262","doi-asserted-by":"publisher","first-page":"5280","DOI":"10.3748\/wjg.v28.i36.5280","volume":"28","author":"JB Warner","year":"2022","unstructured":"Warner JB, Guenthner SC, Hardesty JE, McClain CJ, Warner DR, Kirpich IA. Liver-specific drug delivery platforms: Applications for the treatment of alcohol-associated liver disease. World J Gastroenterol. 2022;28:5280\u201399.","journal-title":"World J Gastroenterol"},{"key":"1780_CR263","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2174\/0113816128297329240305071103","volume":"30","author":"R Deshmukh","year":"2024","unstructured":"Deshmukh R, Singh R, Sharma S, Mishra AK, Harwansh RK. A Snapshot of selenium-enclosed nanoparticles for the management of cancer. Curr Pharm Des. 2024;30:841\u201358.","journal-title":"Curr Pharm Des"},{"key":"1780_CR264","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.2147\/IJN.S319255","volume":"16","author":"M El-Nabarawi","year":"2021","unstructured":"El-Nabarawi M, Nafady M, Elmenshawe S, Elkarmalawy M, Teaima M. Liver targeting of daclatasvir via tailoring sterically stabilized bilosomes: fabrication, comparative in vitro\/in vivo appraisal and biodistribution studies. Int J Nanomed. 2021;16:6413\u201326.","journal-title":"Int J Nanomed"},{"key":"1780_CR265","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.pdpdt.2019.01.027","volume":"25","author":"S Taghizadeh","year":"2019","unstructured":"Taghizadeh S, Alimardani V, Roudbali PL, Ghasemi Y, Kaviani E. Gold nanoparticles application in liver cancer. Photodiagn Photodyn Ther. 2019;25:389\u2013400.","journal-title":"Photodiagn Photodyn Ther"},{"key":"1780_CR266","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/nano11071702","volume":"11","author":"K Kozics","year":"2021","unstructured":"Kozics K, Sramkova M, Kopecka K, Begerova P, Manova A, Krivosikova Z, et al. Pharmacokinetics, biodistribution, and biosafety of PEGylated gold nanoparticles in vivo. Nanomaterials. 2021;11:1702.","journal-title":"Nanomaterials"},{"key":"1780_CR267","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.nano.2014.03.004","volume":"10","author":"M Raoof","year":"2014","unstructured":"Raoof M, Corr SJ, Zhu C, Cisneros BT, Kaluarachchi WD, Phounsavath S, et al. Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma. Nanomed: Nanotechnol Biol Med. 2014;10:1121\u201330.","journal-title":"Nanomed: Nanotechnol Biol Med"},{"key":"1780_CR268","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2174\/138920010791110827","volume":"11","author":"J Wang","year":"2010","unstructured":"Wang J, Sui M, Fan W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Curr Drug Metab. 2010;11:129\u201341.","journal-title":"Curr Drug Metab"},{"key":"1780_CR269","doi-asserted-by":"publisher","first-page":"657665","DOI":"10.3389\/fonc.2021.657665","volume":"11","author":"S-M Wang","year":"2021","unstructured":"Wang S-M, Yang P-W, Feng X-J, Zhu Y-W, Qiu F-J, Hu X-D, et al. Apigenin inhibits the growth of hepatocellular carcinoma cells by affecting the expression of microRNA transcriptome. Front Oncol. 2021;11:657665.","journal-title":"Front Oncol"},{"key":"1780_CR270","doi-asserted-by":"publisher","first-page":"681477","DOI":"10.3389\/fphar.2021.681477","volume":"12","author":"EF DeRango-Adem","year":"2021","unstructured":"DeRango-Adem EF, Blay J. Does oral apigenin have real potential for a therapeutic effect in the context of human gastrointestinal and other cancers? Front Pharmacol. 2021;12:681477.","journal-title":"Front Pharmacol"},{"key":"1780_CR271","doi-asserted-by":"publisher","first-page":"111778","DOI":"10.1016\/j.colsurfb.2021.111778","volume":"204","author":"S Ganguly","year":"2021","unstructured":"Ganguly S, Dewanjee S, Sen R, Chattopadhyay D, Ganguly S, Gaonkar R, et al. Apigenin-loaded galactose tailored PLGA nanoparticles: A possible strategy for liver targeting to treat hepatocellular carcinoma. Colloids Surf, B. 2021;204:111778.","journal-title":"Colloids Surf, B"},{"key":"1780_CR272","doi-asserted-by":"publisher","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","volume":"601","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.","journal-title":"Int J Pharm"},{"key":"1780_CR273","first-page":"389","volume":"52","author":"CH Wu","year":"2018","unstructured":"Wu CH, Lan CH, Wu KL, Wu YM, Jane WN, Hsiao M, et al. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy. Int J Oncol. 2018;52:389\u2013401.","journal-title":"Int J Oncol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01780-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01780-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01780-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:04:42Z","timestamp":1745845482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01780-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":273,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1780"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01780-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"18 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}